Corporate News

2023

07 December
Company Update
27 November
Holding(s) in Company
27 September
Directorate appointment
08 September
Partnership with VIDA to streamline adoption of advanced MRI of the lungs
07 September
Half-year Report - Amendment
07 September
Half-year Report
05 September
Reimbursement code price range for XENOVIEW
29 August
CMS grants reimbursement code for the Polarean XENOVIEW™ MRI Technology
21 August
Holding(s) in Company
15 August
Notice of results
09 August
Holding(s) in Company
07 August
Exercise of Warrants, PDMR Dealing, Issue of Equity and Total Voting Rights
03 August
Polarean Receives Clearance for New MRI Chest Coil
31 July
University of Missouri Health Care to begin clinical imaging with XENOVIEWTM Conversion
27 July
Block Listing Six Monthly Return
30 June
Exercise of Warrants, PDMR Dealing, Issue of Equity and Total Voting Rights
28 June
Result of AGM
21 June
Appointment of Dr. Christopher von Jako as new CEO
02 June
Collaboration with Philips to be featured at ISMRM 2023
02 June
Extension of Warrants
26 May
Final results for the year ended 31 December 2022
11 May
First clinical scan using XENOVIEWTM in Cincinnati
03 May
Featured at 2023 ATS Respiratory Innovation Summit
26 April
First order for XENOVIEWTM gas blend received from Cincinnati Children’s Hospital Medical Center
17 April
Appointment of Dan Brague as consultant
14 March
RESTORATION OF TRADING ON AIM
14 March
Request for temporary suspension from trading on AIM to be lifted
13 March
TEMPORARY SUSPENSION OF TRADING ON AIM
13 March
Silicon Valley Bank Relationship, Request for temporary suspension from trading on AIM
15 February
Investor presentation
13 February
Company Update
01 February
FDA grants New Chemical Entity designation for XENOVIEW
27 January
Block Listing Six Monthly Return

2019

24 December
New System Delivery and Installation
12 November
New System Delivery and Installation
08 November
Grant of Options
07 November
Completion of patient enrolment for Clinical Trials and PDMR Appointment
11 October
Director Dealing
11 October
Polarean notes statement from Amphion Innovations
09 October
Holding(s) in Company
03 October
Polarean notes statement from Amphion Innovations
25 September
Polarean notes statement from Amphion Innovations
24 September
Half-year Report
10 September
Polarean notes statement from Amphion Innovations
10 September
New System Installation
09 August
Polarean notes statement from Amphion Innovations
05 August
Phase III Clinical Trials update First patient enrolment at University of Cincinnati
31 July
Total Voting Rights
30 July
Holding(s) in Company
30 July
Holding(s) in Company
29 July
Holding(s) in Company
25 July
Result of AGM
24 July
Exercise of Warrants
22 July
Placing to raise £2.1 million
11 July
New System Order
27 June
Final Results
13 June
Investor Symposium presentations available online
11 June
Phase III Clinical Trials - Update
05 June
New System Order
23 May
Grant of Share Options
23 May
London Investor Symposium Wednesday 12 June 2019
21 May
Third tranche of $3m paediatric lung disease imaging study grant confirmed
13 May
Phase III Clinical Trial Update
30 April
Total Voting Rights
29 April
Appointment of Chief Financial Officer
02 April
Exercise of Warrants
01 April
Amphion Innovations plc - Pledge of Polarean shares
15 February
New System Order with the University of British Columbia
24 January
Appointment of Nominated Adviser and Broker
21 January
Holding(s) in Company
03 January
Holding(s) in Company

About Us

Share Price

-
GBp
-
-
-

Latest Annual Report

 


 

Important dates

07 Sep
Half Year Report
28 Jun
Annual General Meeting

Investor Alert

Sign up for Email Alerts